Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03923257 (Phase I Trial of Peptide Receptor Radiotherapy), which is not on this map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03923257 phase1 / phase2withdrawnnot on this mapstarted 2020, after this paper: background citation
Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.Frontiers in endocrinology · 2025Trial
- Review
- Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children.European journal of nuclear medicine and molecular imaging · 2025Observational
- Cation Exchange Protocol to Radiolabel Rare-Earth Nanoparticles with Yttrium-90 for Radiotherapy and for Magnetic Resonance Imaging.ACS applied materials & interfaces · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Survival impact of [European journal of nuclear medicine and molecular imaging · 2025Article
- The University of Iowa Neuroendocrine Tumor Clinic.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Article
- Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.European journal of nuclear medicine and molecular imaging · 2024Article
- Interaction of Radiopharmaceuticals with Somatostatin Receptor 2 Revealed by Molecular Dynamics Simulations.Journal of chemical information and modeling · 2023Article
- Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?Acta pharmaceutica Sinica. B · 2023Review
- Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated withEuropean journal of nuclear medicine and molecular imaging · 2022Article
- Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.Cancers · 2022Review
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Addition ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.International journal of molecular sciences · 2021Review
- Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.International journal of molecular sciences · 2020Review
- Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study forMedical physics · 2019Article
- Technical Note: Single time point dose estimate for exponential clearance.Medical physics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Yusuf MendaDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa yusuf-menda@uiowa.edu.
Mark T MadsenDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Thomas M O'DorisioDepartment of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
John J SunderlandDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
G Leonard WatkinsDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Joseph S DillonDepartment of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Sarah L MottHolden Comprehensive Cancer Center, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Michael K SchultzDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
Gideon K D ZambaDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa; and.
David L BushnellDepartment of Radiology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
M Sue O'DorisioDepartment of Pediatrics, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa.
University of Iowa · US
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0MProject 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI ODORISIO, THOMAS · 2015 to 2021
$13.2MImage-guided Diagnosis and Therapy of Neuroendocrine TumorsR01CA167632 · NCI · UNIVERSITY OF IOWA · PI MENDA, YUSUF, O'DORISIO, M. SUE · 2012 to 2016
$2.6MNCI NIH HHS P50 CA174521NCI NIH HHS R01 CA167632
Abstract
Pretherapy PET with
Indexed as
AdolescentAdultAgedBone MarrowFemaleHumansKidneyMaleMiddle AgedNeuroendocrine TumorsOctreotidePositron Emission Tomography Computed TomographyPrecision MedicineProspective StudiesRadiopharmaceuticalsRadiotherapy Dosage90Y-octreotide, DOTA-Tyr(3)-OctreotideRadiopharmaceuticalsReceptors, SomatostatinYttrium Radioisotopes90Y-DOTATOCdosimetryneuroendocrinepeptide receptor radiotherapyradiobiology/dosimetryradionuclide therapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03923257ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.